Invex Health Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Invex Health Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $300.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Invex Health Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $300.0K Trade | TransData Nexus

Invex Health Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $300.0K Total Trade · DGFT Verified

Invex Health Private Limited is an Indian pharmaceutical exporter with a total trade value of $300.0K across 2 products in 1 therapeutic categories. Based on 6 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Melphalan ($150.0K), Rituximab ($150.0K), .

Invex Health Private Limited — Export Portfolio & Destination Treemap

Invex Health Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Invex Health Private Limited? — Company Overview & Market Position

Invex Health Private Limited is a privately held pharmaceutical company established on December 19, 2018, in Neemuch, Madhya Pradesh, India. The company is registered under the Corporate Identification Number (CIN) U24290MP2018PTC047309 and is classified as a private non-government company. Initially known as Invax Healthcare Private Limited, the company rebranded to Invex Health Private Limited to better reflect its strategic focus. The registered office is located at 84 Jawahar Nagar, Neemuch, Madhya Pradesh, 458441, India.

The authorized and paid-up capital of Invex Health Private Limited is ₹5.00 million each, indicating a modest financial base. The company operates in the pharmaceutical sector, specializing in the development and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of July 2025, Invex Health Private Limited employed between 11 to 50 individuals, reflecting its status as a small to medium-sized enterprise. The company's official website is www.invexhealth.com, providing information about its products, services, and contact details.

What Does Invex Health Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Melphalan$150.0K

Product Portfolio — Top 2 by Export Value

Invex Health Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Melphalan	Advanced Oncology	$150.0K	3	1.2%	5
2	Rituximab	Advanced Oncology	$150.0K	3	0.8%	6

Invex Health Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $300.0K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Invex Health Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Invex Health Private Limited operates manufacturing facilities in Neemuch, Madhya Pradesh, and Mumbai, Maharashtra. The Neemuch facility serves as the registered office, while the Mumbai facility is situated at Office No. 105, 1st Floor, The Summit Business Bay-Omkar, Andheri East, Mumbai – 400093. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed. However, the company's focus on finished pharmaceutical formulations suggests that these facilities are equipped to handle the production of various dosage forms, including tablets, capsules, syrups, and injections.

3Key Leadership

The leadership team of Invex Health Private Limited comprises two directors:

Anudesh Goyal: Serving as a director since the company's inception on December 19, 2018.

Neha Agrawal: Also a director since December 19, 2018.

Detailed information regarding other key executives, such as the CEO, CFO, and other senior management personnel, is not publicly available. The company's leadership appears to be relatively small, which is common in privately held companies of this size.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Invex Health Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Invex Health Private Limited's export activities, as reported by TransData Nexus, indicate a total export value of $300,000 USD across six shipments, with products spanning one therapeutic category. The top two exported products are Melphalan and Rituximab, each contributing $150,000 USD to the total export value. Both products are classified under the Advanced Oncology therapeutic category, highlighting the company's focus on oncology treatments. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed. This lack of publicly available information suggests that Invex Health Private Limited may not have established a significant presence in these regulated markets.

2Emerging Markets

Invex Health Private Limited has established distributor partnerships across more than 25 countries, including the USA, Canada, UAE, Southeast Asia, and India. This global reach indicates the company's strategic focus on emerging markets. While the company emphasizes its commitment to providing quality and affordable products in these regions, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available. The absence of such information suggests that Invex Health Private Limited may not have pursued WHO prequalification or similar certifications for its products.

Invex Health Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Invex Health Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The absence of such information suggests that the company may not have pursued FDA approvals for its products, potentially limiting its market access in the United States. This lack of FDA approvals could impact the company's ability to market and sell its products in the U.S. market, which is known for its stringent regulatory requirements.

2WHO & EU GMP

Invex Health Private Limited's website highlights its focus on in-licensing and out-licensing innovative products, as well as its participation in global tenders. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The absence of such certifications suggests that the company may not have pursued these international quality standards, which are often essential for market access in various regions.

3CDSCO & Indian Regulatory

Invex Health Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Invex Health Private Limited operates in the competitive pharmaceutical industry, focusing on the oncology segment with products like Melphalan and Rituximab. While specific market share data is not publicly available, the company's export data indicates a concentration on a limited number of products within a single therapeutic category. This strategic focus may position Invex Health Private Limited to compete effectively in niche markets. However, the limited diversification in product offerings could expose the company to competitive pressures from larger, more diversified pharmaceutical companies operating in the oncology space.

2Key Differentiators

Invex Health Private Limited emphasizes its focus on in-licensing and out-licensing innovative products, as well as its participation in global tenders. The company's product portfolio spans various therapy areas, including pharmaceuticals, nutraceuticals, and medical devices. This breadth of offerings may provide a competitive advantage in catering to diverse market needs. However, the company's limited publicly available information regarding regulatory approvals and certifications may pose challenges in establishing credibility and trust with potential partners and customers.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Invex Health Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Invex Health Private Limited's export data indicates a total export value of $300,000 USD across six shipments, with products spanning one therapeutic category. The

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Invex Health Private Limited

How many pharmaceutical products does Invex Health Private Limited export from India?

Invex Health Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Melphalan ($150.0K), Rituximab ($150.0K). Total export value is $300.0K.

What is Invex Health Private Limited's total pharmaceutical export value?

Invex Health Private Limited's total pharmaceutical export value is $300.0K, based on 6 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Invex Health Private Limited cover?

Invex Health Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Invex Health Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.